ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: First, we treated 2 ALK+ ALCL cell lines (KARPAS-299 and SU-DHL-1) and 2 ALK− PTCL cell lines (MyLa and DERL7) with the ALKi Crizotinib (Figure 7A) and found, as expected, that the ALK+ cells were about 10 times as sensitive as the ALK− cells (Figure 7B).